Choosing and using Drosophila models to characterize modifiers of Huntington's disease

被引:10
|
作者
Green, Edward W. [1 ]
Giorgini, Flaviano [1 ]
机构
[1] Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England
关键词
Drosophila; genetic modifier; genetic screening; Huntington's disease; neurodegeneration; TARGETED GENE-EXPRESSION; AGE-OF-ONSET; MUTANT HUNTINGTIN; POLYGLUTAMINE TOXICITY; LIFE-SPAN; NEURODEGENERATION; SUPPRESSION; INACTIVATION; INHIBITORS; BEHAVIOR;
D O I
10.1042/BST20120072
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HD (Huntington's disease) is a fatal inherited gain-of-function disorder caused by a polyQ (polyglutamine) expansion in the htt (huntingtin protein). Expression of mutant htt in model organisms is sufficient to recapitulate many of the cellular defects found in HD patients. Many groups have independently developed Drosophila models of HD, taking advantage of its rapid life cycle, carefully annotated genome and well-established molecular toolkits. Furthermore, unlike simpler models, Drosophila have a complex nervous system, displaying a range of carefully co-ordinated behaviours which offer an exquisitely sensitive readout of neuronal disruption. Measuring HD-associated changes in behaviour in Drosophila therefore offers a window into the earliest stages of HD, when therapeutic interventions might be particularly effective. The present review describes a number of recently developed Drosophila models of HD and offers practical guidance on the advantages and disadvantages of various experimental approaches that can be used to screen these models for modifiers of mutant htt-mediated toxicity.
引用
收藏
页码:739 / 745
页数:7
相关论文
共 50 条
  • [11] Huntington's disease
    Ha, Ainhi D.
    Fung, Victor S. C.
    CURRENT OPINION IN NEUROLOGY, 2012, 25 (04) : 491 - 498
  • [12] Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms
    Cepeda, Carlos
    Cummings, Damian M.
    Andre, Veronique M.
    Holley, Sandra M.
    Levine, Michael S.
    ASN NEURO, 2010, 2 (02):
  • [13] Huntington's disease: the case for genetic modifiers
    Gusella, James F.
    MacDonald, Marcy E.
    GENOME MEDICINE, 2009, 1
  • [14] Huntington's disease: the case for genetic modifiers
    James F Gusella
    Marcy E MacDonald
    Genome Medicine, 1
  • [15] Pcaf Modulates Polyglutamine Pathology in a Drosophila Model of Huntington's Disease
    Bodai, Laszlo
    Pallos, Judit
    Thompson, Leslie Michels
    Marsh, J. Lawrence
    NEURODEGENERATIVE DISEASES, 2012, 9 (02) : 104 - 106
  • [16] A C-terminal ataxin-2 disordered region promotes Huntingtin protein aggregation and neurodegeneration in Drosophila models of Huntington's disease
    Huelsmeier, Joern
    Walker, Emily
    Bakthavachalu, Baskar
    Ramaswami, Mani
    G3-GENES GENOMES GENETICS, 2021, 11 (12):
  • [17] Deciphering the key mechanisms leading to alteration of lipid metabolism in Drosophila model of Huntington's disease
    Singh, Akanksha
    Agrawal, Namita
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2021, 1867 (07):
  • [18] Gut Bacteria Regulate the Pathogenesis of Huntington's Disease in Drosophila Model
    Chongtham, Anjalika
    Yoo, Jung Hyun
    Chin, Theodore M.
    Akingbesote, Ngozi D.
    Huda, Ainul
    Marsh, J. Lawrence
    Khoshnan, Ali
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [19] Animal models of Huntington's disease and their applicability to novel drug discovery and development
    Upadhayay, Shubham
    Jamwal, Sumit
    Kumar, Puneet
    EXPERT OPINION ON DRUG DISCOVERY, 2023, 18 (05) : 527 - 538
  • [20] Influence of Species Differences on the Neuropathology of Transgenic Huntington's Disease Animal Models
    Li, Xiao-Jiang
    Li, Shihua
    JOURNAL OF GENETICS AND GENOMICS, 2012, 39 (06) : 239 - 245